Skip to main content

Table 3 Profiles of patients who underwent liver resection after neoadjuvant HAIC

From: Role and limitation of neoadjuvant hepatic arterial infusion chemotherapy in advanced hepatocelluar carcinoma patients with Child-Pugh class A

Case Gender/age Etiology HAIC cycle AFP (initial-preoperative) Bilobar HCC PVTT Extrahepatic metastasis Resection Margin Recurrence (time/site) (months) Survival time (months)
1 F/73 HBV 6 3170–99.4 No Yes Yes (LNs) Minor Tumor-free No 81
2 M/44 HBV 6 5845–2.8 No Yes No Major Tumor-free No 120
3 M/61 HBV 8 11.74–8.8 No Yes No Major Tumor-free 18/lung 46
4 M/40 HBV 4 158.0–432.2 No Yes No Major Tumor-free 2/liver 18
5 M/42 HBV 6 950–60.2 No Yes No Major Tumor-free 13/lung 31
6 M/53 HBV 4 369.9–337.7 No Yes No Major Tumor-free 2/liver 10
7 F/48 HBV 6 188663–40762 Yes No No Minor Tumor-free 3/liver 37
8 M/44 HBV 7 7.5–6.7 Yes Yes No Minor Tumor-free 10/liver 33
9 M/56 HBV 3 911.6–23.1 No Yes No Major Tumor-free 47/liver 68
10 M/47 HBV 6 1038–701.1 Yes No No Major Tumor-free 13/liver, lung 43
11 F/39 HBV 8 121000–6047 Yes Yes No Major Tumor-involved 7/liver 20
12 M/46 HBV 6 188.6–17.2 Yes Yes No Minor Tumor-free 3/liver 67
  1. HAIC hepatic arterial infusion chemotherapy, HBV hepatitis B, AFP alpha-fetoprotein, HCC hepatocellular carcinoma, PVTT portal vein tumor thrombus, LN lymph node